THE ULTIMATE GUIDE TO AGO TUMOR

Molecular typing is predicated on molecular genetic screening and is not but routinely offered. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple damaging) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 could be handy, but a pro